343-69-1

Basic information

• Product Name: 6-TRIFLUOROMETHYL ISATIN
• Synonyms: 6-TRIFLUOROMETHYL ISATIN;6-(Trifluoromethyl)indoline-2,3-dione;6-(Trifluoromethyl)-1H-indole-2,3-dione;6-fluoromethylisatin;6-(trifluoroMethyl)-2,3-dihydro-1H-indole-2,3-dione
• CAS NO: 343-69-1
• Molecular Formula: C₉H₄F₃NO₂
• Molecular Weight: 215.13
• EINECS: 1312995-182-4
• Product Categories: blocks;IndolesOxindoles
• Mol File: 343-69-1.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Density: 1.525 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 8.76±0.20(Predicted)
• CAS DataBase Reference: 6-TRIFLUOROMETHYL ISATIN(CAS DataBase Reference)
• NIST Chemistry Reference: 6-TRIFLUOROMETHYL ISATIN(343-69-1)
• EPA Substance Registry System: 6-TRIFLUOROMETHYL ISATIN(343-69-1)

Safety Data

• Hazardous Substances Data: 343-69-1(Hazardous Substances Data)

Usage

Description

6-TRIFLUOROMETHYL ISATIN, also known as 6-(Trifluoromethyl)-1H-indole-2,3-dione, is an organic compound with a molecular structure that features a trifluoromethyl group attached to an isatin backbone. 6-TRIFLUOROMETHYL ISATIN is known for its potential applications in various fields, particularly in the pharmaceutical industry, due to its unique chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
6-TRIFLUOROMETHYL ISATIN is used as a key intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and reactivity make it a valuable building block in the development of new drugs with specific therapeutic properties.
Used in Antiviral Applications:
6-TRIFLUOROMETHYL ISATIN is used as a starting material for the preparation of substituted 3,4-dihydroquinazoline derivatives. These derivatives have demonstrated potential in the treatment and prophylaxis of hepatitis B virus (HBV) infection, offering a promising avenue for the development of new antiviral therapies.

Upstream product

• 159684-36-3 (2-tert-Butoxycarbonylamino-4-trifluoromethyl-phenyl)-oxo-acetic acid ethyl ester 
• 109134-07-8 t-butyl<3-(trifluoromethyl)phenyl>-carbamate 
• 95-92-1 oxalic acid diethyl ester 
• 98-16-8 3-trifluoromethylaniline 
• 141940-36-5 tert-butyl (2-(trifluoromethyl)phenylamino)formate 
• 404-83-1 N-(3-trifluoromethylphenyl)-2-oxyiminoacetamide 
• 13544-43-9 6-(trifluoromethyl)-1H-indole 

Downstream Products

• 402-13-1 2-amino-4-trifluoromethylbenzoic acid 
• 183720-17-4 3-(5-Chloro-2-hydroxyphenyl)-1,3-dihydro-3-hydroxy-6-(trifluoromethyl)-2H-indol-2-one 
• 187523-36-0 (-)-BMS-204352 

Relevant articles and documents

Synthesis and biological evaluation of novel 2-oxo-1,2-dihydroquinoline-4-carboxamide derivatives for the treatment of esophageal squamous cell carcinoma

No new and effective treatments have been approved for the treatment of esophageal squamous cell carcinoma (ESCC) in the past decade. Cisplatin and 5-fluoruracil are the most commonly used drugs for this disease. In order to develop a new class of drugs effective in our ESCC phenotypic screens, we began a systematic approach to generate novel compounds based on the 2-oxo-1,2-dihydroquinoline-4-carboxamide fragment. Herein, we report on the synthesis and initial assessment of 55 new analogues in two ESCC cell lines. Some of the active analogues with IC50 values around 10 μM were tested in three additional cell lines. Our structure-activity relationships revealed remarkable alterations in the anti proliferative activities upon modest chemical modifications and autophagy modulation is a suggested mechanism of action.

Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors

A series of N-benzylated isatin oximes were developed as inhibitors of the mitogen-activated kinase, JNK3. X-ray crystallographic structures aided in the design and synthesis of novel, selective compounds, that inhibit JNK3, but not p38 MAP kinase and provided key insights into understanding the behavior of gatekeeper residue methionine-146 in determining target selectivity for this series.

Enantioselective synthesis of BMS-204352 (MaxiPost) using N-fluoroammonium salts of cinchona alkaloids (F-CA-BF4).

The enantioselective synthesis of a potent Maxi-K potassium channel opener (BMS-204352) mediated by N-fluoroammonium salts of cinchona alkaloids is described. Two synthetic pathways were evaluated. An ee as high as 88% was achieved (>99% after a single re